ERBB2 and neoplasm: In a breast cancer xenograft mouse model, anti-HER2 glycoconjugate containing a cleavable or noncleavable maytansine linker demonstrated complete tumor regression, while both the MMAE containing glycoconjugate and conventional lysine conjugate showed partial tumor suppression.